Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q4 2020 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q4: 2021-02-25 Earnings Summary

EPS of -$1.41 misses by $0.10
 | Revenue of $44.05M (24.28% Y/Y) beats by $4.17M

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2020 Results Conference Call February 25, 2021 8:00 AM ET

Company Participants

Holly Manning - Director, IR
Dr. Jackie Fouse - CEO
Dr. Chris Bowden - Chief Medical Officer
Darrin Miles - Chief Commercial Officer
Jonathan Biller - CFO and Head, Legal and Corporate Affairs

Conference Call Participants

Peter Lawson - Barclays
Tyler Van Buren - Piper Sandler
Anupam Rama - JP Morgan
Kennen MacKay - RBC Capital Markets
Michael Schmidt - Guggenheim
Marc Frahm - Cowen & Company
John Newman - Canaccord
Kalpit Patel - Oppenheimer
Christopher Liu - SVB Leerink

Operator

Good morning, and welcome to Agios’ Fourth Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Holly Manning, Director of Investor Relations.

Holly Manning

Thank you, operator. Good morning, everyone, and welcome to Agios' fourth quarter 2020 conference call.

You can access slides for today's call by going to the Investors section of our website, agios.com. With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs. Dr. Bruce Car, our Chief Scientific Officer, will join for Q&A.

Before we get started, I would like to remind everyone, some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the

Recommended For You

About AGIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AGIO